CoChat

Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents

Doshi, Lalit S, Brahma, Manoja Kumar, Bahirat, Umakant A, Dixit, Amol V, Nemmani, Kumar VS · 2010 · Expert Opinion on Investigational Drugs
Cited by 59

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

IMPORTANCE OF THE FIELD: PPARgamma full agonists (pioglitazone and rosiglitazone) are the mainstay drugs for the treatment of type 2 diabetes; however, mechanism-based side effects have limited their full therapeutic potential. In recent years, much progress has been achieved in the discovery and development of selective PPARgamma modulators (SPPARgammaMs) as safer alternatives to PPARgamma full agonists. AREAS COVERED IN THIS REVIEW: This review focuses on the preclinical and clinical data of all the SPPARgammaMs discovered so far, retrieved by searching PubMed, Prous Integrity database and company news updates from 1999 to date. WHAT THE READER WILL GAIN: Here we thoroughly discuss SPPARgammaMs' mode of action, briefly examine new ways to identify superior SPPARgammaMs, and finally, compare and contrast the pharmacological and safety profile of various agents. TAKE HOME MESSAGE: The preclinical and clinical findings clearly suggest that selective PPARgamma modulators have the potential to become the next generation of PPARgamma agonists: effective insulin sensitizers with a superior safety profile to that of PPARgamma full agonists.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1517/13543781003640169

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 59

Metadata

Authors
Doshi, L. S., Brahma, M. K., Bahirat, U. A., Dixit, A. V., & Nemmani, K. V.
Venue
Expert Opinion on Investigational Drugs
Published
2010-03-31
Volume
19
Issue
4
Pages
489-512
ISSN
  • 1354-3784 (ISSN-L)
  • 1744-7658
OpenAlex
W2126855139
Cited by
59
References
13
FWCI
3.07
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents. https://app.cochat.ai/papers/10.1517/13543781003640169
The paper
Doshi, L. S., Brahma, M. K., Bahirat, U. A., Dixit, A. V., & Nemmani, K. V. (2010). Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543781003640169

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.